Atorvastatin or Rosuvastatin

Phase 3

SSeoul National University Bundang Hospital

Atorvastatin or Rosuvastatin is one of 3 therapeutic programs targeting Acute Coronary Syndromes (ACS). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Acute Coronary Syndromes (ACS)Not yet recruiting

Acute Coronary Syndromes (ACS)Phase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Acute Coronary Syndromes (ACS)

#DrugCompanyPhaseTrials

Leqvio

Novartis

Approved

1 2

Zetia

OOrganon and Co

Approved

1 3

Atorvastatin or Rosuvastatin

SSeoul National University Bundang Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

ApprovedNot yet recruiting

Acute Coronary Syndromes (ACS)

NCT07799779

Clinical

Trials by Indication[1]

Acute Coronary Syndromes (ACS)1 trial

Statin, Ezetimibe, and Inclisiran for Plaque Regression in Acute Coronary Syndrome: A Randomized Controlled Trial (SEsiR-ACS Trial)

Not yet recruiting·SSeoul National University Bundang Hospital·Approved·NCT07799779·294 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Atorvastatin or Rosuvastatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Atorvastatin or Rosuvastatin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Seoul National University Bundang Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSeoul National University Bundang Hospital

Atorvastatin or Rosuvastatin

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Acute Coronary Syndromes (ACS)1 trial

References

Drug Info

Quick Facts

Related News